Danaher Praises Pall for Returning Biopharma to ‘High Growth Norm’

Strong demand for single-use technologies has returned double-digit growth for Pall, contributing to a “return to normality” for Danaher Corporation’s life sciences business.

For its second quarter 2018, Danaher Corporation reported total revenues across its life sciences businesses of US$1.6 billion (€1.4 billion), up 16% over the same period last year.

The multinational attributed much of the growth to Pall Corporation – the filtration, separations and purification firm it acquired for $13.6 billion in 2015 – though CEO Tom Joyce also acknowledged some of his firm’s other units.

“We have the biopharma at Beck LS, at SCIEX and Molecular Devices, all would indicate that things are very much tracking as you would expect in the biopharma market,” he told stakeholders, “with double-digit growth in Pall in the biopharma market led by continued strength and single-use technology.”

The firm does not break down Pall or its other businesses’ specific sales figures.

Joyce added the strength of single-use has made Danaher feel “very good about the life science end markets right now,” following a dip in growth experienced by his firm and other vendors last year.

“A year ago, you saw some softness in that market, you saw issues with a couple of big customers, not just ours, but customers that were broadly served through the market, you saw some inventory adjustments. I think a lot of that is past now,” he said.

“We’re in a market that is sort of returned to normal. But normal in the case of biopharma means a very good growth market and you saw that based on the broad-based strength at Pall.”

Pall and Kaneka

In related news, Pall has struck a deal to supply Kaneka Corporation’s KanCapA Protein A supplier in a range of its pre-packed columns and high throughput screening tools.

“Increasing demand for more targeted and personalized medicines is driving growth and development in the mAb manufacturing market. In combination with our industry-leading portfolio of downstream process equipment, KANEKA KanCapA 3G sorbent offers a complete solution to customers looking to make these products,” said Mario Philips, Vice President and General Manager at Pall Biotech.

“Through the collaboration with the KANEKA team we are able to ensure consistency, quality and reliability with an industry-leading sorbent that enables customers to continuously improve their bioprocesses.”